MedicaidPrior AuthMedium impact
Beleodaq® (belinostat) (New)
Humana·IN · Oncology, Hematology·Medicaid
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana has implemented a new prior authorization policy for Beleodaq (belinostat), an IV cancer medication used to treat relapsed or refractory peripheral T-cell lymphoma. Prior authorization will be required for all Medicaid patients in Indiana starting January 1, 2026, with specific criteria including diagnosis requirements and drug interaction exclusions.
Action Required
By January 1, 2026: Billing team must update prior authorization workflows for Beleodaq (belinostat) IV infusions for Indiana Medicaid patients. Ensure providers document relapsed or refractory peripheral T-cell lymphoma diagnosis and verify patients are not on concomitant Istodax, Zolinza, or Folotyn therapy before prescribing. Visit www.humana.com/PAL for specific medical coding requirements. Claims without prior authorization will be denied.